Sandeep Kunwar
Founder & Chief Executive Officer Precision NeuroMed
Seminars
Wednesday 18th February 2026
TALK 2: Reactivation of a Tumor Stem Cell–Targeted Oncolytic Protein for Glioblastoma Enabled by a Scalable, Reproducible Delivery Platform
- Discuss the molecular targeting and mechanism of action of the IL13-PE38QQR cytotoxic payload
- Highlight clinical outcomes from early-stage studies of IL13-PE38QQR delivered via convection-enhanced delivery (CED)
- Present a next-generation CED drug-delivery platform designed to be scalable and reproducible, addressing the key limitations that hindered prior clinical trials
